Pfizer Q1 revenues $13.7B (-8% YoY), adjusted EPS $0.92 (+12%); reaffirms FY2025 guidance

PFIZER INC

Q1 revenues $13.7B, down 8% YoY; reported diluted EPS $0.52 (down 5%), adjusted diluted EPS $0.92 (up 12%).
Reaffirms FY2025 guidance: revenue $61-$64B, adjusted diluted EPS $2.80-$3.00, with no share buybacks anticipated.
Expands cost realignment: additional $1.2B net savings by 2027 (SI&A focus) plus $500M R&D reinvestment by 2026; one-time costs $1.6B and $600M respectively.
Paxlovid revenue fell $1.5B operationally (75% drop); Vyndaqel family grew 33% operationally; Comirnaty up 62% operationally.
Paid $2.4B in cash dividends ($0.43/shr) in Q1; gross leverage below previously stated target; $3.3B remaining buyback authority.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.